Afficher la notice abrégée

dc.contributor.authorSánchez Moreno, Paola 
dc.contributor.authorBoulaiz Tassi, Houria 
dc.contributor.authorOrtega Vinuesa, Juan Luis 
dc.contributor.authorPeula-García, José Manuel
dc.contributor.authorAránega Jiménez, Antonia 
dc.date.accessioned2013-10-21T09:17:54Z
dc.date.available2013-10-21T09:17:54Z
dc.date.issued2012
dc.identifier.citationSánchez-Moreno, P.; et al. Novel Drug Delivery System Based on Docetaxel-Loaded Nanocapsules as a Therapeutic Strategy Against Breast Cancer Cells. International Journal of Molecular Sciences, 13(4): 4906-4919 (2012). [http://hdl.handle.net/10481/28494]es_ES
dc.identifier.issn1422-0067
dc.identifier.issn1661-6596
dc.identifier.urihttp://hdl.handle.net/10481/28494
dc.description.abstractIn the field of cancer therapy, lipid nanocapsules based on a core-shell structure are promising vehicles for the delivery of hydrophobic drugs such as docetaxel. The main aim of this work was to evaluate whether docetaxel-loaded lipid nanocapsules improved the anti-tumor effect of free docetaxel in breast cancer cells. Three docetaxel-loaded lipid nanocapsules were synthesized by solvent displacement method. Cytotoxic assays were evaluated in breast carcinoma (MCF-7) cells treated by the sulforhodamine B colorimetric method. Cell cycle was studied by flow cytometry and Annexin V-FITC, and apoptosis was evaluated by using propidium iodide assays. The anti-proliferative effect of docetaxel appeared much earlier when the drug was encapsulated in lipid nanoparticles than when it was free. Docetaxel-loaded lipid nanocapsules significantly enhanced the decrease in IC50 rate, and the treated cells evidenced apoptosis and a premature progression of the cell cycle from G(1) to G(2)-M phase. The chemotherapeutic effect of free docetaxel on breast cancer cells is improved by its encapsulation in lipid nanocapsules. This approach has the potential to overcome some major limitations of conventional chemotherapy and may be a promising strategy for future applications in breast cancer therapy.es_ES
dc.description.sponsorshipThe study was supported in part by grants from the Science and Innovation Ministry through the project REF: SAF2009-12295 and MAT2010-20370 (European FEDER support included), the “Instituto de Salud Carlos III” (Fondo de Investigación Sanitaria project No. P07-FQM03099) and the “Consejería de Innovación, Ciencia y Tecnología de la Junta de Andalucía” (Spain), by projects of excellence P07-FQM-2496 and P07-FQM03099 and P10-CTS-6270.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 3.0 Licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es_ES
dc.subjectLipid nanoparticleses_ES
dc.subjectDocetaxel es_ES
dc.subjectDrug deliveryes_ES
dc.subjectBreast canceres_ES
dc.titleNovel Drug Delivery System Based on Docetaxel-Loaded Nanocapsules as a Therapeutic Strategy Against Breast Cancer Cellses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/ijms13044906es_ES


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License